Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023)

Dare Bioscience's Current Deferred Revenue history spans 3 years, with the latest figure at $205206.0 for Q3 2023.

  • For Q3 2023, Current Deferred Revenue changed N/A year-over-year to $205206.0; the TTM value through Sep 2023 reached $205206.0, changed N/A, while the annual FY2016 figure was $2.5 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $205206.0 in Q3 2023 per DARE's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $205206.0 in Q3 2023 to a low of $205206.0 in Q3 2023.